• Indications now show the wording of the SmPC itself (section 4.1) with the date the text was retrieved, and say so when EMA's medicine table states different age limits. • Labels that bundle several presentations (an intravenous and a subcutaneous form, tablets and granules, several vaccine doses) now show the indications and posology of every presentation, not only the first. • "At a glance" keywords are grouped by indication passage; exclusions ("excluding patients with …") never produce a badge, and a passage that may contain more than one indication shows a notice instead of badges. • Cell & gene therapy list: Casgevy's record names both FDA applications and the current age limit; Waskyra's record carries its age and transplant conditions. • Carvykti's detail sheet notes the switch from conditional to standard EU authorisation (19 April 2024). • Clearer wording throughout: "file integrity verified" against the data release, CDER novel approvals, daily EU data refresh with the Union Register cross-check.

EU/US label comparison, rebuilt: each EU medicine is now paired with the US label of the same product (by brand name), or - when no US product of that name exists - with the US label of the same active substance, clearly marked as a different product. Fixed-dose combinations, conjugates and over-the-counter labels are no longer offered as counterparts. Sections the extract could not capture now say so instead of claiming the label lacks them; US tables keep their merged headers. Europe tab: new "Withdrawn" view next to Approved and Expected, listing EU medicines that are no longer authorised or never were - marketing authorisation withdrawn, expired, lapsed, revoked or suspended, application refused, or withdrawn by the applicant - with the event date and the original authorisation date. When a search matches only such a product, the Approved view says so and shows it. US tab: every FDA-licensed cell and gene therapy is searchable by brand, generic name, manufacturer, class or indication, including products without an openFDA label yet. Each entry shows the official FDA approval date, product class and, where available, the EU authorisation date. Biomarkers tab: the FDA list of authorised companion diagnostics is now built in - 226 authorisations for 70 devices (FDA list of 23 July 2026), searchable by device, manufacturer, drug, indication, biomarker or submission number. Every biomarker entry shows the matching FDA-authorised tests next to the EU test method required by the SmPC, and the FDA group-labelling table is included. Also: label libraries refreshed (EU SmPCs and US labels, September 2026), searches no longer overwritten by slower earlier results, the search box keeps each tab's query, the detail panel closes on a new search, the Withdrawn view no longer carries the comparison cards of authorised medicines, pinch-to-zoom enabled, clearer wording in the guide and biomarker index, updated privacy notes.

• Comparison tray: a drug class pulled up with “Compare all” now clears itself when you start a new search, so an unrelated query no longer carries the old comparison along. A new clear button empties the tray with one tap. • Cell & gene therapies: 9 additional CBER-approved cell and gene therapies added to the US advanced-therapy snapshot. • Refreshed bundled EU and US data (September 2026).

Clearer guidance when an EU search comes up empty: DrugRadar now explains that nationally authorised medicines (for example via AIFA in Italy or BfArM in Germany) are not part of the EMA's central catalogue, and points to the national registers instead. Also includes the latest bundled EU dataset and small refinements.

Just-announced FDA approvals The US tab now shows brand-new FDA approval announcements the moment the FDA press office publishes them - days before they appear in the openFDA database. Searching for a just-approved drug now explains that its database entry is pending, with a link to the announcement, instead of showing an empty result.

NEW: Medical Devices tab • US device market entries, live from the FDA: original PMA approvals (high-risk devices — the device equivalent of a new-drug approval), 510(k) clearances and De Novo grants, and recent recalls • Search by device, manufacturer, or specialty; every entry links to the official FDA database record NEW: Drug+Device badge • EU medicines with an integral device — implants, inhalers, pre-filled pens — are now flagged on the Europe tab, with a plain-language glossary entry IMPROVED: Clearer answers for brand-new medicines • Searching for a medicine that has just received a positive CHMP opinion now explains its exact status and the estimated EU decision date, instead of showing "no match" IMPROVED: Biomarkers tab • Plain-language explanation for every biomarker and a curated reference link • The medicines a biomarker unlocks now link straight to their EMA product page

New in this update: • Biomarkers & Companion Diagnostics — a new Europe-centered tab indexing the actionable biomarkers behind targeted therapy. For each biomarker (EGFR, ALK, BRAF, HER2, PD-L1, BRCA, MSI-H and more) see the validated test method (per the SmPC, under the EU IVD Regulation) and the EU-authorised medicines the result unlocks — then compare them side by side, down to the full label. • Search by molecular target — type a target such as EGFR, PD-1, PARP or CD20 to instantly pull up the matching drug class(es) for side-by-side comparison. As always: an information aid for professionals, not medical advice — always verify against the official EMA SmPC.

Compare a whole drug class side by side — now from the Europe tab too. Type a disease (for example multiple sclerosis, renal cell carcinoma, psoriasis, or myasthenia gravis) and DrugRadar lines up its therapies with their EU and US approval dates and companies. • Read the full EU SmPC and US prescribing information for every drug in a class, in one comparison. • Much larger disease library spanning oncology, neurology, immunology and more. • Smarter, more accurate disease search. • Stability fixes and refinements.

Compare a whole drug class at once. Search a disease - like CML - and compare all its treatments side by side (for example, the six CML tyrosine kinase inhibitors), each with its FDA and EMA approval dates, drug class, and indication. Plus the latest FDA and EMA approvals, including newly added cell & gene therapies.

• Fixed: some recently authorised EU medicines were missing from the Europe list (e.g. seladelpar/Lyvdelzi for PBC, zuranolone/Zurzuvae) • New: "Back to drug" button when jumping from a medicine to its Phase 3 trials • Fixed: view now scrolls to the top when switching tabs • Smoother scrolling when opening and closing a medicine's detail sheet • The information-only disclaimer is now re-confirmed every 30 days • Updated in-app feature tour, including how often the data refreshes

Corrected wording in the Europe tab: medicines in the "Expected" list are now described as awaiting the European Commission decision, without implying the outcome of the CHMP opinion. The decision date shown remains an estimate.

NEW IN 1.2 • Home-screen widget — see the next expected EU decisions for the conditions you follow, at a glance. • Add to Calendar — export estimated EU decision dates as calendar events, with a reminder three days ahead. • Saved searches — bookmark any search and re-run it with one tap, separately on each tab. • Find drugs from your home screen — every EU medicine is now in iOS system search, jumping straight to its detail page. • New quick tour — "What you can do here" walks you through every feature (? button in the header). • Fixes and refinements throughout. Estimated dates remain estimates — always verify against official sources. For information only; not medical advice.